We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Rare but High-Risk: New-Onset RBBB After TAVR Strongly Linked to Pacemaker Need

MedXY Editorial Team•Dec 17, 2025•Cardiology
Conduction DisturbancesPacemakerTAVR

Highlights

  • Post-TAVR new-onset RBBB occurs in approximately 5.3 cases per 1,000 procedures.
  • Nearly half of affected patients require a permanent pacemaker within one year, most within the first week after the procedure.
  • Post-TAVR PR interval length ≥230 ms and PR change ≥24 ms help identify high-risk patients.

Background

Transcatheter aortic valve replacement (TAVR) is a well-established treatment for severe aortic stenosis in patients across surgical risk profiles. Conduction disturbances following TAVR are common, particularly new-onset left bundle branch block (LBBB), often necessitating further cardiac rhythm management. In contrast, right bundle branch block (RBBB) post-TAVR has been considered uncommon and less studied. Given the anatomical proximity of the His-Purkinje system to the implanted valve, even rare disturbances may carry important implications for patient care.

Study Design

This multicenter retrospective cohort analysis was conducted across seven Israeli hospitals, evaluating 7,782 consecutive TAVR patients. All participants underwent baseline electrocardiograms within 48 hours prior to the procedure and daily follow-up ECGs thereafter. The study identified new-onset RBBB and monitored patients for one year, focusing on absolute pacing indications (API), defined as high-grade atrioventricular block or alternating bundle branch block. Permanent pacemaker implantation (PPI) rates, timing, and associations with PR interval changes were analyzed.

Key Findings

Among the cohort, 41 cases of post-TAVR new-onset RBBB were identified, corresponding to an incidence of 5.3 per 1,000 procedures (95% CI: 3.8–7.1). Within one year, 46.3% (19 patients) required PPI. Most PPIs were performed during the index hospitalization, with all but one API occurring before discharge. Late API was documented in just one patient due to delayed AV block. Analysis of electrophysiological markers revealed that a post-TAVR PR interval cutoff of 228 ms provided a specificity of 95% and sensitivity of 50% in predicting API. Similarly, a PR change (Δ PR) of ≥24 ms yielded 80% specificity and 83% sensitivity. Importantly, survival outcomes suggested a nonsignificant advantage for patients not undergoing PPI, although this finding warrants further study.

Timing of Conduction Deterioration

The majority of conduction system deterioration occurred within the first week after TAVR, underscoring the critical early post-procedure window for monitoring and intervention.

Risk Stratification Utility

Post-TAVR PR interval prolongation and Δ PR are practical markers for identifying patients at high risk for progressive conduction disease. PR ≥230 ms or Δ PR ≥24 ms should prompt heightened surveillance or consideration for early pacing decisions, especially in centers with high patient volumes and rapid discharge protocols.

Expert Commentary

The rarity of RBBB should not diminish its clinical significance post-TAVR. While LBBB remains the more frequent and studied conduction block, this research shows that RBBB carries a proportionally higher risk of progressing to conditions requiring pacing. From an anatomical standpoint, injury or mechanical compression of the right bundle branch can occur due to deployment depth and prosthesis geometry, particularly in self-expanding valves. Clinicians should integrate PR interval metrics into early postoperative monitoring workflows. However, PR interval thresholds, while useful, should not be the sole determinant; patient comorbidities, valve type, and procedural complexity also warrant consideration.

Limitations include the retrospective design and reliance on continuous ECG surveillance, which may not be feasible in all settings. Additionally, the study did not differentiate outcomes based on valve type, a factor known to influence conduction complication rates.

Conclusion

Post-TAVR new-onset RBBB, although rare, is strongly associated with progressive conduction abnormalities and a high likelihood of requiring permanent pacing, typically within one week post-procedure. PR interval assessment is a valuable, practical tool for risk stratification. Clinicians should remain vigilant in early post-TAVR monitoring, particularly for patients with significant PR prolongation. Prospective validation of suggested PR thresholds in diverse procedural contexts could further enhance predictive accuracy and patient outcomes.

Funding and ClinicalTrials.gov

No specific funding disclosures were noted. No registered clinical trial number provided.

References

Michowitz Y, Yagel O, Shrem M, Elbaz-Greener G, Tovia-Brodie O, Goldenberg GR, Danon A, Katz M, Taieb P, Loewenstein I, Shamia D, Kezerle L, Dvir D, Glikson M, Belhassen B. New-Onset RBBB After Transcatheter Aortic Valve Replacement: Incidence and Risk Factors for Permanent Pacemaker Implantation. JACC Clin Electrophysiol. 2025 Nov;11(11):2458-2467. doi: 10.1016/j.jacep.2025.06.013. Epub 2025 Aug 6. PMID: 40767801.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: Evidence and Insights from the NOTION-4 TrialThe NOTION-4 trial demonstrates that 3 months of DOAC therapy post-TAVR reduces early HALT incidence compared to SAPT, but benefits diminish after discontinuation, highlighting nuanced balance between thrombosis prevention and bleeding riskSep 1, 2026Seven-Year Health Outcomes After TAVR Versus SAVR in Low-Risk Aortic Stenosis Patients: Insights from the PARTNER 3 TrialIn low-risk severe aortic stenosis patients, both TAVR and SAVR provide sustained health status improvements over seven years, with TAVR offering faster early recovery but similar long-term health outcomes.Aug 18, 2026Seven-Year Valve Durability Outcomes Comparing Transcatheter and Surgical Aortic Valve Replacement: Insights from the PARTNER 3 Randomized TrialAn evidence-based review of the 7-year durability of transcatheter versus surgical aortic bioprosthetic valves in low-risk severe aortic stenosis patients, highlighting comparable long-term structural performance and need for reinterventionJun 24, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis: What PARTNER 2A Adds to the Long-Term TAVR Evidence BaseThe PARTNER 2A 10-year data show higher mortality and reintervention with balloon-expandable SAPIEN XT TAVR versus surgery in intermediate-risk patients, driven mainly by transthoracic access. Contemporary 10-year SAPIEN 3 data, however, suJun 17, 2026
Myocardial Fibrosis Predicts Outcomes in Asymptomatic Severe Aortic Stenosis, But Early Valve Replacement May Not Offer Universal BenefitThe EVOLVED trial reveals that higher myocardial fibrosis burden associates with adverse events in asymptomatic severe aortic stenosis patients, yet early intervention benefits appear nuanced—showing promise for reducing hospitalizations inApr 17, 2026
Superior Long-Term Hemodynamics with Self-Expanding Valves in Small Failed Bioprostheses: 3-Year Insights from the LYTEN TrialThe 3-year analysis of the LYTEN trial reveals that self-expanding valves (SEV) significantly outperform balloon-expandable valves (BEV) in hemodynamic metrics for valve-in-valve TAVR in patients with small surgical bioprostheses, although Mar 3, 2026